OP43A
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) Agarose Conjugate
slurry (Liquid), clone DO-1, Calbiochem®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
Pricing and availability is not currently available.
biological source
mouse
Quality Level
antibody product type
primary antibodies
clone
DO-1, monoclonal
form
slurry (Liquid)
contains
≤0.1% sodium azide as preservative
species reactivity
feline, human
should not react with
mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
General description
Immunoaffinity purified mouse monoclonal antibody, generated by immunizing Balb/c mice with the specified immunogen and fusing splenocytes with X63AG8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) Agarose Conjugate is validated for use in Affinity Chromatography, Immunoprecipitation for the detection of p53 (Ab-6) (Pantropic).
Application
Affinity Chromatography (see comments)
Immunoprecipitation (15 µl beads/sample; see application references)
Immunoprecipitation (15 µl beads/sample; see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
Agarose suspension in PBS.
Other Notes
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Agarose conjugate has also been reported to work with affinity chromotography. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Gatei et al.
Oncogene, 20(3), 289-294 (2001-04-21)
Cells from patients with the genetic disorder ataxia-telangiectasia (A-T) are hypersensitive to ionizing radiation and radiomimetic agents, both of which generate reactive oxygen species capable of causing oxidative damage to DNA and other macromolecules. We describe in A-T cells constitutive
Ryan T Pitman et al.
Oncotarget, 4(5), 761-771 (2013-06-27)
T-oligo, an 11-base oligonucleotide homologous to the 3'-telomeric overhang, is a novel, potent therapeutic modality in melanoma and multiple other tumor types. T-oligo is proposed to function in a manner similar to experimental disruption of the telomere overhang and induces
Alain Beliveau et al.
Proceedings of the National Academy of Sciences of the United States of America, 104(11), 4431-4436 (2007-03-16)
Ectopically expressed hTERT enables p16(INK4A)(-) human mammary epithelial cells to proliferate in the absence of growth factors, a finding that has led to the hypothesis that hTERT has growth regulatory properties independent of its role in telomere maintenance. We now
Marie R Webster et al.
Molecular cell, 77(3), 633-644 (2019-12-15)
Metastatic melanoma is an aggressive disease, despite recent improvements in therapy. Eradicating all melanoma cells even in drug-sensitive tumors is unsuccessful in patients because a subset of cells can transition to a slow-cycling state, rendering them resistant to most targeted
Christina Kåbjörn Gustafsson et al.
Sarcoma, 2014, 208786-208786 (2014-08-06)
Myxoid/round cell liposarcoma (MLS/RCLS) is the second most common liposarcoma type and characterized by the fusion oncogenes FUS-DDIT3 or EWSR1-DDIT3. Previous analysis of cell cycle regulatory proteins revealed a prominent expression of G1-cyclins, cyclin dependent kinases, and their inhibitors but
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
